Supplementary Figure 5 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial

L. Collet; Maude Ardin; David Venet; Justine Berthet; Sarah Barrin; Isabelle Treilleux; Jean‐Christophe Noël; Marianne Leheurteur; Jérôme Meunier; Leïla Bengrine-Lefèvre; Mathilde Martinez; Frank Priou; Frédèric Selle; Pierre-Alexandre Just; Guillaume Bataillon; Françoise Rothé; Christos Sotiriou; Christophe Caux; Bertrand Dubois; Isabelle Ray‐Coquard; Olivia Le Saux

doi:10.1158/1078-0432.29760190

Key Points

MAIN FINDING: The research identifies biological pathways associated with pd-l1 expression in high-grade serous ovarian cancer.
KEY EVIDENCE: Immune and stroma cell abundance was estimated using data from the Australian Ovarian Cancer Study dataset.
APPROACH: The investigation utilized supplementary figures to analyze tumor microenvironment characteristics in metastases and tubo-ovaries.
SIGNIFICANCE: Understanding cell abundance in tumors may inform treatment strategies targeting pd-l1 expression in ovarian cancer.

Implication

Analysis reveals immune and stroma cell abundance in metastases, suggesting implications for PD-L1 expression in ovarian cancer.

Abstract

Supplementary Figure 5. Biological pathways and immune and stroma cells abundance estimation in metastases and tubo-ovaries in Australian Ovarian Cancer Study (AOCS) dataset.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Collet et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d022b https://doi.org/10.1158/1078-0432.29760190

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 5 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 5 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading